I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

innovation accounts for a substantial portion of recent increases in U.S. life expectancy. Baker and Fugh-Berman claim that my … literature. Baker and Fugh-Berman express deep skepticism about my study's conclusion that medical innovation has played a very …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) — about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma … post-1997 chemotherapy innovation did not exceed $45,551. We also investigate the impact of chemotherapy innovation on the …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …